Pemetrexed



Pemetrexed
Systematic (IUPAC) name
2-[4-[2-(4-amino-2-oxo-3,5,7-triazabicyclo[4.3.0] nona-3,8,10-trien-9-yl)ethyl] benzoyl] aminopentanedioic acid
Identifiers
CAS number 137281-23-3
ATC code L01BA04
PubChem 60843
DrugBank APRD00573
Chemical data
O6 
Mol. mass 427.411 g/mol
Pharmacokinetic data
Bioavailability NA
Protein binding 81%
Metabolism Negligible
Half life 3.5 hours
Excretion Renal
Therapeutic considerations
Licence data

EU US

Pregnancy cat.

D(US)

Legal status

℞-only(US)

Routes IV

Pemetrexed (brand name Alimta®) is a mesothelioma as well as non-small cell lung cancer.

History

The molecular structure of pemetrexed was developed by Edward C. Taylor at Princeton University and clinically developed by Indianapolis based drug maker, Eli Lilly and Company in 2004 year.

Mechanism of action

Pemetrexed is chemically similar to RNA, which are required for the growth and survival of both normal cells and cancer cells.

Clinical use

In February 2004, the cisplatin. In July 2004, the FDA granted approval as a second-line agent for the treatment of non-small cell lung cancer. Trials are currently testing it against esophagus and other cancers.

Patients are required to be on dexamethasone 4mg twice daily) on the day prior, day of, and day after pemetrexed infusion to avoid skin rashes.

 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pemetrexed". A list of authors is available in Wikipedia.